Prevention of CMV infection with valacyclovir vs acyclovir: principal efficacy population
| . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| Time to CMV in blood, BAL, or disease | 0.59 (0.46, 0.76) | < .0001 |
| Time to CMV disease or any positive culture | 0.56 (0.45, 0.71) | < .0001 |
| Time to definitive CMV disease | 0.71 (0.30, 1.65) | .421 |
| Time to CMV in blood | 0.57 (0.44, 0.75) | < .0001 |
| Time to CMV in urine | 0.47 (0.34, 0.66) | < .0001 |
| . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| Time to CMV in blood, BAL, or disease | 0.59 (0.46, 0.76) | < .0001 |
| Time to CMV disease or any positive culture | 0.56 (0.45, 0.71) | < .0001 |
| Time to definitive CMV disease | 0.71 (0.30, 1.65) | .421 |
| Time to CMV in blood | 0.57 (0.44, 0.75) | < .0001 |
| Time to CMV in urine | 0.47 (0.34, 0.66) | < .0001 |